Active, not recruitingPhase 2NCT04480502
ENVASARC: Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma
Studying Undifferentiated pleomorphic sarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Tracon Pharmaceuticals Inc.
- Principal Investigator
- Charles Theuer, MD, PhD, M.D., Ph.DTracon Pharmaceuticals Inc.
- Intervention
- Envafolimab(biological)
- Enrollment
- 207 enrolled
- Eligibility
- 12 years · All sexes
- Timeline
- 2020 – 2024
Study locations (30)
- University of Arizona, Tucson, Arizona, United States
- University of California, Los Angeles, Los Angeles, California, United States
- Sarcoma Oncology Research Center, Santa Monica, California, United States
- Stanford University, Stanford, California, United States
- University of Colorado, Aurora, Colorado, United States
- Mayo Clinic, Jacksonville, Jacksonville, Florida, United States
- University of Miami, Miami, Florida, United States
- H. Lee Moffitt Cancer Center, Tampa, Florida, United States
- Northwestern University, Evanston, Illinois, United States
- Johns Hopkins University, Baltimore, Maryland, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- Dana Farber Cancer Institute, Boston, Massachusetts, United States
- University of Michigan, Ann Arbor, Michigan, United States
- Mayo Clinic Rochester, Rochester, Minnesota, United States
- Washington University in St. Louis, St Louis, Missouri, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04480502 on ClinicalTrials.govOther trials for Undifferentiated pleomorphic sarcoma
Additional recruiting or active studies for the same condition.